Liposome carriers in chemotherapy of leishmaniasis
US4186183A · kind A · utility
166Cited by
0References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 29, 1978 |
| Grant date | Jan 29, 1980 |
| Priority date | — |
| Expiry date | Mar 29, 1998 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An improved method is provided for the chemotherapy of leishmanial infections. The anti-leishmanial agent is encapsulated within liposomes and the liposome-encapsulated drug is injected into the body. Subject use of a liposome carrier has produced marked enhancement of the effectiveness and duration of anti-leishmanial action of meglumine antimoniate, and of sodium stibogluconate, drugs which are recommended widely for therapy of leishmaniasis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.